Cargando…

CRISPR/Cas9 technology: applications in oocytes and early embryos

CRISPR/Cas9, a highly versatile genome-editing tool, has garnered significant attention in recent years. Despite the unique characteristics of oocytes and early embryos compared to other cell types, this technology has been increasing used in mammalian reproduction. In this comprehensive review, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yi-ran, Yin, Tai-lang, Zhou, Li-quan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594749/
https://www.ncbi.nlm.nih.gov/pubmed/37875936
http://dx.doi.org/10.1186/s12967-023-04610-9
_version_ 1785124715232231424
author Zhang, Yi-ran
Yin, Tai-lang
Zhou, Li-quan
author_facet Zhang, Yi-ran
Yin, Tai-lang
Zhou, Li-quan
author_sort Zhang, Yi-ran
collection PubMed
description CRISPR/Cas9, a highly versatile genome-editing tool, has garnered significant attention in recent years. Despite the unique characteristics of oocytes and early embryos compared to other cell types, this technology has been increasing used in mammalian reproduction. In this comprehensive review, we elucidate the fundamental principles of CRISPR/Cas9-related methodologies and explore their wide-ranging applications in deciphering molecular intricacies during oocyte and early embryo development as well as in addressing associated diseases. However, it is imperative to acknowledge the limitations inherent to these technologies, including the potential for off-target effects, as well as the ethical concerns surrounding the manipulation of human embryos. Thus, a judicious and thoughtful approach is warranted. Regardless of these challenges, CRISPR/Cas9 technology undeniably represents a formidable tool for genome and epigenome manipulation within oocytes and early embryos. Continuous refinements in this field are poised to fortify its future prospects and applications. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04610-9.
format Online
Article
Text
id pubmed-10594749
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105947492023-10-25 CRISPR/Cas9 technology: applications in oocytes and early embryos Zhang, Yi-ran Yin, Tai-lang Zhou, Li-quan J Transl Med Review CRISPR/Cas9, a highly versatile genome-editing tool, has garnered significant attention in recent years. Despite the unique characteristics of oocytes and early embryos compared to other cell types, this technology has been increasing used in mammalian reproduction. In this comprehensive review, we elucidate the fundamental principles of CRISPR/Cas9-related methodologies and explore their wide-ranging applications in deciphering molecular intricacies during oocyte and early embryo development as well as in addressing associated diseases. However, it is imperative to acknowledge the limitations inherent to these technologies, including the potential for off-target effects, as well as the ethical concerns surrounding the manipulation of human embryos. Thus, a judicious and thoughtful approach is warranted. Regardless of these challenges, CRISPR/Cas9 technology undeniably represents a formidable tool for genome and epigenome manipulation within oocytes and early embryos. Continuous refinements in this field are poised to fortify its future prospects and applications. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04610-9. BioMed Central 2023-10-24 /pmc/articles/PMC10594749/ /pubmed/37875936 http://dx.doi.org/10.1186/s12967-023-04610-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Zhang, Yi-ran
Yin, Tai-lang
Zhou, Li-quan
CRISPR/Cas9 technology: applications in oocytes and early embryos
title CRISPR/Cas9 technology: applications in oocytes and early embryos
title_full CRISPR/Cas9 technology: applications in oocytes and early embryos
title_fullStr CRISPR/Cas9 technology: applications in oocytes and early embryos
title_full_unstemmed CRISPR/Cas9 technology: applications in oocytes and early embryos
title_short CRISPR/Cas9 technology: applications in oocytes and early embryos
title_sort crispr/cas9 technology: applications in oocytes and early embryos
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594749/
https://www.ncbi.nlm.nih.gov/pubmed/37875936
http://dx.doi.org/10.1186/s12967-023-04610-9
work_keys_str_mv AT zhangyiran crisprcas9technologyapplicationsinoocytesandearlyembryos
AT yintailang crisprcas9technologyapplicationsinoocytesandearlyembryos
AT zhouliquan crisprcas9technologyapplicationsinoocytesandearlyembryos